GlassScriptPhysician profile
Cheruba Prabakar
NPI 1679701858
$7,173.85
in general payments reported to CMS, 2019-2025
19 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $47.08 · 2021: $107 · 2022: $552 · 2023: $2,762 · 2024: $2,724 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,450 · Travel and Lodging: $1,345 · Education: $1,019 · Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,450.00 |
| Travel and Lodging | $1,344.75 |
| Education | $1,019.27 |
| Food and Beverage | $913.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,558.39 | 2021-2023 | |
| Intuitive Surgical, INC. | $1,507.96 | 2019-2025 | |
| Becton, Dickinson and Company | $1,259.89 | 2024 | Bd Onclarity |
| Boston Scientific Corporation | $600.00 | 2019 | |
| Conmed Corporation | $352.20 | 2022 | |
| Astellas Pharma US INC | $258.65 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $145.48 | 2023-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Myosure Tissue Removal Device |
| Abbvie INC. | $103.51 | 2019-2024 | |
| Medtronic, INC. | $89.35 | 2024-2025 | Situate, V-Loc 180 |
| Applied Medical Resources Corporation | $53.14 | 2021 | |
| Coopersurgical, INC. | $42.33 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $41.78 | 2024 | Myfembree |
| Myovant Sciences INC. | $36.16 | 2022 | |
| Meditrina | $31.67 | 2024 | |
| Biogen, INC. | $29.82 | 2025 | Zurzuvae |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $25.48 | 2024 | |
| Penumbra, INC. | $15.07 | 2021 | |
| Allergan, INC. | $11.79 | 2020 | |
| Daiichi Sankyo INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheruba Prabakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.